Completed PHASE1 INTERVENTIONAL 9-arm NCT06117514

Sudapyridine (WX-081) in Healthy Volunteers

A Single-center, Randomized, Double-blind, Placebo-controlled, Dose-ascending Phase I Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of Sudapyridine (WX-081) Tablets in Healthy Chinese Subjects

Sponsor: Shanghai Jiatan Pharmatech Co., Ltd

Conditions Healthy

Interventions Placebo 200mg SAD Placebo tablet MAD Placebo tablet SAD Sudapyridine 100mg SAD Sudapyridine 200mg MAD Sudapyridine 200mg SAD Sudapyridine 300mg MAD Sudapyridine 30mg

Updated 3 times since 2023 Last updated: Nov 2, 2023 Started: Feb 13, 2019 Primary completion: Jul 2, 2020 Completion: Jul 2, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy, this trial is completed. The trial is conducted by Shanghai Jiatan Pharmatech Co., Ltd and has accumulated 3 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Dec 2023 — Jul 2024 [monthly]

Completed PHASE1

First recorded

Feb 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Jiatan Pharmatech Co., Ltd

Data source: Shanghai Jiatan Pharmatech Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China